BR112013017672A2 - composto de imidazo[4,5-c]quinolin-2-ona e seu uso como inibidor duplo de quinase pi3/mtor - Google Patents

composto de imidazo[4,5-c]quinolin-2-ona e seu uso como inibidor duplo de quinase pi3/mtor

Info

Publication number
BR112013017672A2
BR112013017672A2 BR112013017672A BR112013017672A BR112013017672A2 BR 112013017672 A2 BR112013017672 A2 BR 112013017672A2 BR 112013017672 A BR112013017672 A BR 112013017672A BR 112013017672 A BR112013017672 A BR 112013017672A BR 112013017672 A2 BR112013017672 A2 BR 112013017672A2
Authority
BR
Brazil
Prior art keywords
mtor
quinolin
imidazo
dual
compound
Prior art date
Application number
BR112013017672A
Other languages
English (en)
Inventor
Anthony Barda David
Margaret Mader Mary
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR112013017672A2 publication Critical patent/BR112013017672A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112013017672A 2011-01-14 2012-01-11 composto de imidazo[4,5-c]quinolin-2-ona e seu uso como inibidor duplo de quinase pi3/mtor BR112013017672A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161432958P 2011-01-14 2011-01-14
PCT/US2012/020897 WO2012097039A1 (en) 2011-01-14 2012-01-11 Imidazo [4, 5 -c] quinolin- 2 -one compound and its use as pi3 kinase / mtor dual inhibitor

Publications (1)

Publication Number Publication Date
BR112013017672A2 true BR112013017672A2 (pt) 2018-09-18

Family

ID=45531593

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013017672A BR112013017672A2 (pt) 2011-01-14 2012-01-11 composto de imidazo[4,5-c]quinolin-2-ona e seu uso como inibidor duplo de quinase pi3/mtor

Country Status (39)

Country Link
US (2) US8440829B2 (pt)
EP (1) EP2663564B1 (pt)
JP (1) JP5891247B2 (pt)
KR (1) KR101561360B1 (pt)
CN (1) CN103282364B (pt)
AR (1) AR084551A1 (pt)
AU (1) AU2012205619B2 (pt)
BR (1) BR112013017672A2 (pt)
CA (1) CA2824760C (pt)
CL (1) CL2013002005A1 (pt)
CO (1) CO6731133A2 (pt)
CR (1) CR20130289A (pt)
CY (1) CY1116007T1 (pt)
DK (1) DK2663564T3 (pt)
DO (1) DOP2013000158A (pt)
EA (1) EA022163B1 (pt)
EC (1) ECSP13012764A (pt)
ES (1) ES2531891T3 (pt)
GT (1) GT201300180A (pt)
HK (1) HK1188454A1 (pt)
HR (1) HRP20150135T1 (pt)
HU (1) HUE024426T2 (pt)
IL (1) IL227165A (pt)
JO (1) JO3003B1 (pt)
ME (1) ME02019B (pt)
MX (1) MX2013008185A (pt)
MY (1) MY164705A (pt)
PE (1) PE20140864A1 (pt)
PL (1) PL2663564T3 (pt)
PT (1) PT2663564E (pt)
RS (1) RS53828B1 (pt)
SG (1) SG191744A1 (pt)
SI (1) SI2663564T1 (pt)
SV (1) SV2013004496A (pt)
TN (1) TN2013000237A1 (pt)
TW (1) TWI518086B (pt)
UA (1) UA109921C2 (pt)
WO (1) WO2012097039A1 (pt)
ZA (1) ZA201304757B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3003B1 (ar) 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor
US9050345B2 (en) 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
US20160264570A1 (en) * 2013-11-15 2016-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Method of blocking transmission of malarial parasite
TWI609687B (zh) 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
TW201703769A (zh) 2015-05-08 2017-02-01 美國禮來大藥廠 用於癌症的組合療法
GB201516504D0 (en) * 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
MX2018007225A (es) 2015-12-15 2018-08-01 Lilly Co Eli Terapia combinada para el cancer.
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
WO2017180389A1 (en) * 2016-04-12 2017-10-19 Eli Lilly And Company Combination therapy with notch and cdk4/6 inhibitors for the treatment of cancer
JP6911048B2 (ja) * 2016-04-12 2021-07-28 イーライ リリー アンド カンパニー がんの処置において使用するための、Ｎｏｔｃｈ阻害剤およびＰＩ３Ｋ／ｍＴＯＲ阻害剤を用いた併用療法
CN109475629A (zh) 2016-05-20 2019-03-15 伊莱利利公司 用notch和pd-1或pd-l1抑制剂的组合治疗
WO2018017410A1 (en) 2016-07-22 2018-01-25 Eli Lilly And Company Combination therapy of abemaciclib and a pi3 kinase/mtor dual inhibitor for use in the treatment of breast cancer
WO2018063873A1 (en) * 2016-09-27 2018-04-05 Eli Lilly And Company Combination therapy of abemaciclib and a pi3 kinase/mtor dual inhibitor for use in the treatment of pancreatic cancer
EP3525796A1 (en) 2016-10-12 2019-08-21 Eli Lilly and Company Targeted treatment of mature t-cell lymphoma
EP4269594A3 (en) 2017-02-17 2023-12-20 Fred Hutchinson Cancer Center Combination therapies for treatment of bcma-related cancers and autoimmune disorders
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
CN110386932A (zh) 2018-04-20 2019-10-29 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
US10980784B2 (en) 2018-06-15 2021-04-20 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
WO2020081329A1 (en) * 2018-10-18 2020-04-23 Camp4 Therapeutics Corporation Methods and compositions for modulating pcsk9 and angptl3 expression
EP4069223A4 (en) 2019-12-05 2023-12-20 Janssen Pharmaceutica NV RAPAMYCIN ANALOGS AND THEIR USES
AU2020468487B2 (en) 2020-09-21 2024-02-29 Wei Zhong Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo(4,5-c) quinolin-2-one compounds with blood-brain barrier penetrable capability
EP3992191A1 (en) 2020-11-03 2022-05-04 Deutsches Krebsforschungszentrum Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
AR046845A1 (es) * 2003-11-21 2005-12-28 Novartis Ag Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas
PT1687305E (pt) 2003-11-21 2008-10-17 Novartis Ag Derivados de 1h-imidazoquinolina como inibidores de proteína quinase
CA2598656A1 (en) * 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinoline compounds and methods
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US8088790B2 (en) 2005-11-04 2012-01-03 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods
US8329721B2 (en) 2006-03-15 2012-12-11 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods
WO2010038165A1 (en) * 2008-09-30 2010-04-08 Pfizer Inc. Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions
US20100311714A1 (en) 2009-06-04 2010-12-09 Pascal Furet 1H-IMIDAZO[4,5-c]QUINOLINONE COMPOUNDS
BRPI1010621A2 (pt) 2009-06-04 2016-06-21 Novartis Ag derivado de imidazoquinolinonas, sua composição farmacêutica e seu uso
AU2009349135A1 (en) * 2009-06-30 2012-02-16 Piramal Enterprises Limited Imidazo [4,5-c]quinoline derivatives and their use in the treatment of tumors and/or inflammation
AR084731A1 (es) * 2010-12-06 2013-06-05 Piramal Life Sciences Ltd Derivados de imidazoquinolina sustituidos
JO3003B1 (ar) 2011-01-14 2016-09-05 Lilly Co Eli مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor

Also Published As

Publication number Publication date
ME02019B (me) 2015-05-20
PL2663564T3 (pl) 2015-05-29
PE20140864A1 (es) 2014-07-19
CN103282364A (zh) 2013-09-04
NZ611541A (en) 2015-02-27
EP2663564B1 (en) 2014-12-17
CL2013002005A1 (es) 2013-12-27
DOP2013000158A (es) 2013-11-30
CY1116007T1 (el) 2017-01-25
AU2012205619A1 (en) 2013-06-27
JO3003B1 (ar) 2016-09-05
JP5891247B2 (ja) 2016-03-22
US20120184577A1 (en) 2012-07-19
UA109921C2 (uk) 2015-10-26
CN103282364B (zh) 2015-06-17
TWI518086B (zh) 2016-01-21
TN2013000237A1 (en) 2014-11-10
EA022163B1 (ru) 2015-11-30
US20130237562A1 (en) 2013-09-12
EA201390823A1 (ru) 2013-12-30
SG191744A1 (en) 2013-08-30
MX2013008185A (es) 2013-08-21
CA2824760C (en) 2016-03-15
TW201307343A (zh) 2013-02-16
KR20130116302A (ko) 2013-10-23
WO2012097039A1 (en) 2012-07-19
EP2663564A1 (en) 2013-11-20
PT2663564E (pt) 2015-02-24
RS53828B1 (en) 2015-06-30
US8440829B2 (en) 2013-05-14
US8658668B2 (en) 2014-02-25
MY164705A (en) 2018-01-30
CA2824760A1 (en) 2012-07-19
JP2014502638A (ja) 2014-02-03
SV2013004496A (es) 2017-11-07
AR084551A1 (es) 2013-05-22
CR20130289A (es) 2013-10-07
IL227165A (en) 2016-06-30
GT201300180A (es) 2014-04-08
HK1188454A1 (en) 2014-05-02
ECSP13012764A (es) 2013-09-30
HRP20150135T1 (en) 2015-03-13
KR101561360B1 (ko) 2015-10-16
ZA201304757B (en) 2014-12-23
CO6731133A2 (es) 2013-08-15
ES2531891T3 (es) 2015-03-20
SI2663564T1 (sl) 2015-01-30
HUE024426T2 (en) 2016-01-28
AU2012205619B2 (en) 2015-05-21
DK2663564T3 (en) 2015-01-12

Similar Documents

Publication Publication Date Title
BR112013017672A2 (pt) composto de imidazo[4,5-c]quinolin-2-ona e seu uso como inibidor duplo de quinase pi3/mtor
SMT201700005B (it) 4-(8-metossi-1-((1-metossipropan-2-il)-2-(tetraidro-2h-piran-4-il)-1h-imidazo[4,5- c]chinolin-7-il)-3,5-dimetilisossazolo e suo uso come inibitore di bromodominio
AP3709A (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
BRPI0817681A2 (pt) Compostos de tienopirimidina e pirazolopirimidina e seu uso como inibidores de mtor quinase e pi3 quinase
EP2945632A4 (en) HETEROBICCLOSUBSTITUTED [1,2,4] TRIAZOLO [1,5-C] CHINAZOLINE-5-AMINE COMPOUNDS WITH A2A ANTAGONISTIC PROPERTIES
BR112013011520A2 (pt) pirazolo piridinas e pirazolo piridinas e seu uso como inibidores de tyk2
BR112013005523A2 (pt) composto como inibidores de quinase c-met e seus usos
BR112012029437A2 (pt) derivados de pirrolo[2,3-b]pirazina-7-carboxamida e seu uso como inibidores de jak e syk
BRPI1009118A2 (pt) 3h-imidazo[4,5-c] piridina-6-carboxamidas como agentes anti-inflamatórios
CO7000778A2 (es) Derivados de pirazolopiridina, su procedimiento de preparación y su uso terapéutico
EP2608669A4 (en) NEW PYRAZOLO- [1,5-A-] PYRIMIDINE DERIVATIVES AS ANTI-MTOR HEMMER
BR112014008590A2 (pt) métodos de uso de antagonistas de scd1
DK2710018T3 (da) Makrocykliske forbindelser som proteinkinasehæmmere
CO6791616A2 (es) Derivados de 6-ciclobutil-1,5-dihidro-pirazolo [3,4-d]pirimidin-4-ona y su uso como inhibidores de pde9a
BR112013016030A2 (pt) compostos e seu uso como inibidores de bace
AP3751A (en) Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
DK3254681T3 (da) N-(5s,6s,9r)-5-amino-6-(2,3-difluorphenyl)-6,7,8,9-tetrahydro-5h- cyclohepta[b]pyridin-9-yl-4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1- yl)piperidin-1-carboxylatsalt
DK3483163T3 (da) Triazolo[4,5-d]pyrimidinderivater som cb2-receptorantagonister
BR112013023056A2 (pt) derivados de oxaespiro [2,5] octano e análogos
EP2938344A4 (en) PIPERAZINE-SUBSTITUTED [1,2,4] TRIAZOLO [1,5-C] QUINAZOLINE-5-AMINE COMPOUNDS WITH A2A ANTAGONISTIC PROPERTIES
EP2739627A4 (en) 2,3-DIHYDROIMIDAZO [1,2-C] PYRIMIDIN-5 (1H) -ONE COMPOUNDS AND USE AS INHIBITORS OF LP-PLA2
CO6781555A2 (es) Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-iloxi]-1,4-diaza-espiro[5.5]undecan-5-ona, su uso como medicamento y su preparación
BR112013032360A2 (pt) compostos inibidores de glioblastoma e seu uso
EP2719697A4 (en) PYRIDONAPHTHYRIDINE PI3K / MTOR DUALHEMMER AND THE PREPARATION AND USE THEREOF
BR112014014504A2 (pt) uso de partícula

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements